Vaccine Development for Varicella-Zoster Virus

  • Tomohiko SadaokaEmail author
  • Yasuko Mori
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1045)


Varicella-zoster virus (VZV) is the first and only human herpesvirus for which a licensed live attenuated vaccine, vOka, has been developed. vOka has highly safe and effective profiles; however, worldwide herd immunity against VZV has not yet been established and it is far from eradication. Despite the successful reduction in the burden of VZV-related illness by the introduction of the vaccine, some concerns about vOka critically prevent worldwide acceptance and establishment of herd immunity, and difficulties in addressing these criticisms often relate to its ill-defined mechanism of attenuation. Advances in scientific technologies have been applied in the VZV research field and have contributed toward uncovering the mechanism of vOka attenuation as well as VZV biology at the molecular level. A subunit vaccine targeting single VZV glycoprotein, rationally designed based on the virological and immunological research, has great potential to improve the strategy for eradication of VZV infection in combination with vOka.


Varicella-zoster virus Live attenuated vaccine Next-generation sequencing In vitro latency system VZV-specific cellular immunity Herpes zoster subunit vaccine 



The authors thank Dr. Daniel P. Depledge for helpful discussions and critical reading of the manuscript. This work was supported in part by the Japan Herpesvirus Infections Forum, the Takeda Science Foundation, the Japan Foundation for Pediatric Research, and Japan Society for the Promotion of Science (JSPS KAKENHI JP17K008858).


  1. Amanna IJ, Carlson NE, Slifka MK (2007) Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357:1903–1915. Scholar
  2. Arvin AM, Gilden D (2013) Varicella-zoster virus. In: Knipe DM, Howley PM (eds) Fields virology, 6th edn. Wolters Kluwer Health, Philadelphia, pp 2015–2057Google Scholar
  3. Arvin AM, Kinney-Thomas E, Shriver K et al (1986) Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170. J Immunol 137:1346–1351PubMedGoogle Scholar
  4. Azarkh Y, Gilden DH, Cohrs RJ (2010) Molecular characterization of varicella zoster virus in latently infected human ganglia: physical state and abundance of VZV DNA, quantitation of viral transcripts and detection of VZV-specific proteins. Curr Top Microbiol Immunol 342:229–241. Scholar
  5. Brisson M, Gay NJ, Edmunds WJ, Andrews NJ (2002) Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 20:2500–2507CrossRefPubMedGoogle Scholar
  6. Brunell PA, Novelli VM, Keller PM, Ellis RW (1987) Antibodies to the three major glycoproteins of varicella-zoster virus: search for the relevant host immune response. J Infect Dis 156:430–435CrossRefPubMedGoogle Scholar
  7. Chaves SS, Haber P, Walton K et al (2008a) Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995–2005. J Infect Dis 197(Suppl 2):S170–S177. Scholar
  8. Chaves SS, Zhang J, Civen R et al (2008b) Varicella disease among vaccinated persons: clinical and epidemiological characteristics, 1997–2005. J Infect Dis 197(Suppl 2):S127–S131. Scholar
  9. Chlibek R, Pauksens K, Rombo L et al (2016) Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine 34:863–868. Scholar
  10. Civen R, Chaves SS, Jumaan A et al (2009) The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr Infect Dis J 28:954–959. Scholar
  11. Clarke P, Beer T, Cohrs RJ, Gilden DH (1995) Configuration of latent varicella-zoster virus DNA. J Virol 69:8151–8154PubMedPubMedCentralGoogle Scholar
  12. Coffman RL, Sher A, Seder RA (2010) Vaccine adjuvants: putting innate immunity to work. Immunity 33:492–503. Scholar
  13. Cohen JI (2010) Rodent models of varicella-zoster virus neurotropism. Curr Top Microbiol Immunol 342:277–289. Scholar
  14. Cohrs RJ, Badani H, Baird NL et al (2016) Induction of varicella zoster virus DNA replication in dissociated human trigeminal ganglia. J Neurovirol 23:1–6. Scholar
  15. Cunningham AL, Lal H, Kovac M et al (2016) Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 375:1019–1032. Scholar
  16. Dendouga N, Fochesato M, Lockman L et al (2012) Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine 30:3126–3135. Scholar
  17. Depledge DP, Palser AL, Watson SJ et al (2011) Specific capture and whole-genome sequencing of viruses from clinical samples. PLoS One 6:e27805. Scholar
  18. Depledge DP, Kundu S, Jensen NJ et al (2014) Deep sequencing of viral genomes provides insight into the evolution and pathogenesis of varicella zoster virus and its vaccine in humans. Mol Biol Evol 31:397–409. Scholar
  19. Depledge DP, Yamanishi K, Gomi Y et al (2016) Deep sequencing of distinct preparations of the live attenuated Varicella-Zoster Virus vaccine reveals a conserved Core of attenuating single-nucleotide polymorphisms. J Virol 90:8698–8704. Scholar
  20. Galea SA, Sweet A, Beninger P et al (2008) The safety profile of varicella vaccine: a 10-year review. J Infect Dis 197(Suppl 2):S165–S169. Scholar
  21. Gershon AA, Breuer J, Cohen JI et al (2015) Varicella zoster virus infection. Nat Rev Dis Primers 1:15016. Scholar
  22. Gilden DH, Vafai A, Shtram Y et al (1983) Varicella-zoster virus DNA in human sensory ganglia. Nature 306:478–480CrossRefPubMedGoogle Scholar
  23. Gilden DH, Nagel M, Cohrs R et al (2015) Varicella Zoster Virus in the nervous system. F1000Res.
  24. Gilden DH, White T, Boyer PJ et al (2016) Varicella Zoster Virus infection in granulomatous arteritis of the Aorta. J Infect Dis 213:1866–1871. Scholar
  25. Gomi Y, Imagawa T, Takahashi M, Yamanishi K (2000) Oka varicella vaccine is distinguishable from its parental virus in DNA sequence of open reading frame 62 and its transactivation activity. J Med Virol 61:497–503CrossRefPubMedGoogle Scholar
  26. Gomi Y, Sunamachi H, Mori Y et al (2002) Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus. J Virol 76:11447–11459CrossRefPubMedPubMedCentralGoogle Scholar
  27. Goulleret N, Mauvisseau E, Essevaz-Roulet M et al (2010) Safety profile of live varicella virus vaccine (Oka/Merck): five-year results of the European Varicella Zoster Virus Identification Program (EU VZVIP). Vaccine 28:5878–5882. Scholar
  28. Grose C (1990) Glycoproteins encoded by varicella-zoster virus: biosynthesis, phosphorylation, and intracellular trafficking. Annu Rev Microbiol 44:59–80. Scholar
  29. Hardy I, Gershon AA, Steinberg SP, LaRussa P (1991) The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella vaccine collaborative study group. N Engl J Med 325:1545–1550. Scholar
  30. Harper DR, Kangro HO, Heath RB (1990) Antibody responses in recipients of varicella vaccine assayed by immunoblotting. J Med Virol 30:61–67CrossRefPubMedGoogle Scholar
  31. Hata A, Asanuma H, Rinki M et al (2002) Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 347:26–34. Scholar
  32. Hattori A, Ihara T, Iwasa T et al (1976) Use of live varicella vaccine in children with acute leukaemia or other malignancies. Lancet 2:210. Scholar
  33. Hope-Simpson RE (1965) The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 58:9–20PubMedPubMedCentralGoogle Scholar
  34. Iwasaki S, Motokura K, Honda Y et al (2016) Vaccine-strain herpes zoster found in the trigeminal nerve area in a healthy child: a case report. J Clin Virol 85:44–47. Scholar
  35. Jacquet A, Haumont M, Massaer M et al (2002) Immunogenicity of a recombinant varicella-zoster virus gE-IE63 fusion protein, a putative vaccine candidate against primary infection and zoster reactivation. Vaccine 20:1593–1602CrossRefPubMedGoogle Scholar
  36. Jeon JS, Won YH, Kim IK et al (2016) Analysis of single nucleotide polymorphism among Varicella-Zoster Virus and identification of vaccine-specific sites. Virology 496:277–286. Scholar
  37. Kamiya H, Kato T, Isaji M et al (1984) Immunization of acute leukemic children with a live varicella vaccine (Oka strain). Biken J 27:99–102PubMedGoogle Scholar
  38. Katsushima N, Yazaki N, Sakamoto M et al (1982) Application of a live varicella vaccine to hospitalized children and its follow-up study. Biken J 25:29–42PubMedGoogle Scholar
  39. Kawai K, Yawn BP, Wollan P, Harpaz R (2016) Increasing incidence of herpes zoster over a 60-year period from a population-based study. Clin Infect Dis 63:221–226. Scholar
  40. Kemble GW, Annunziato PW, Lungu O et al (2000) Open reading frame S/L of varicella-zoster virus encodes a cytoplasmic protein expressed in infected cells. J Virol 74:11311–11321CrossRefPubMedPubMedCentralGoogle Scholar
  41. Kester KE, Cummings JF, Ofori-Anyinam O et al (2009) Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 200:337–346. Scholar
  42. Kim JI, Jung GS, Kim YY et al (2011) Sequencing and characterization of Varicella-zoster virus vaccine strain SuduVax. Virol J 8:547. Scholar
  43. Koshizuka T, Ota M, Yamanishi K, Mori Y (2010) Characterization of varicella-zoster virus-encoded ORF0 gene – comparison of parental and vaccine strains. Virology 405:280–288. Scholar
  44. Lal H, Cunningham AL, Chlibek R et al (2015) Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372:2087–2096. Scholar
  45. Leroux-Roels I, Koutsoukos M, Clement F et al (2010) Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems. Vaccine 28:7016–7024. Scholar
  46. Leroux-Roels I, Leroux-Roels G, Clement F et al (2012) A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis 206:1280–1290. Scholar
  47. Leung J, Lopez AS, Blostein J et al (2015) Impact of the US two-dose Varicella vaccination program on the epidemiology of Varicella outbreaks: data from nine states, 2005–2012. Pediatr Infect Dis J 34:1105–1109. Scholar
  48. Levin MJ, Smith JG, Kaufhold RM et al (2003) Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 188:1336–1344. Scholar
  49. Levin MJ, Oxman MN, Zhang JH et al (2008) Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 197:825–835. Scholar
  50. Loparev VN, Rubtcova E, Seward JF et al (2007) DNA sequence variability in isolates recovered from patients with postvaccination rash or herpes zoster caused by Oka varicella vaccine. J Infect Dis 195:502–510. Scholar
  51. Mahalingam R, Wellish M, Wolf W et al (1990) Latent varicella-zoster viral DNA in human trigeminal and thoracic ganglia. N Engl J Med 323:627–631. Scholar
  52. Marin M, Güris D, Chaves SS et al (2007) Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56:1–40PubMedGoogle Scholar
  53. Marin M, Meissner HC, Seward JF (2008) Varicella prevention in the United States: a review of successes and challenges. Pediatrics 122:e744–e751. Scholar
  54. Markus A, Lebenthal-Loinger I, Yang IH et al (2015) An in vitro model of latency and reactivation of Varicella Zoster Virus in human stem cell-derived neurons. PLoS Pathog 11:e1004885. Scholar
  55. Moffat JF, Stein MD, Kaneshima H, Arvin AM (1995) Tropism of varicella-zoster virus for human CD4+ and CD8+ T lymphocytes and epidermal cells in SCID-hu mice. J Virol 69:5236–5242PubMedPubMedCentralGoogle Scholar
  56. Moffat JF, Zerboni L, Kinchington PR et al (1998) Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J Virol 72:965–974PubMedPubMedCentralGoogle Scholar
  57. Nagel MA, Traktinskiy I, Azarkh Y et al (2011) Varicella zoster virus vasculopathy: analysis of virus-infected arteries. Neurology 77:364–370. Scholar
  58. Nagel MA, White T, Khmeleva N et al (2015) Analysis of varicella-zoster virus in temporal arteries biopsy positive and negative for Giant cell arteritis. JAMA Neurol 72:1281–1287. Scholar
  59. Ouwendijk WJD, Choe A, Nagel MA et al (2012a) Restricted varicella-zoster virus transcription in human trigeminal ganglia obtained soon after death. J Virol 86:10203–10206. Scholar
  60. Ouwendijk WJD, Flowerdew SE, Wick D et al (2012b) Immunohistochemical detection of intra-neuronal VZV proteins in snap-frozen human ganglia is confounded by antibodies directed against blood group A1-associated antigens. J Neurovirol 18:172–180. Scholar
  61. Oxman MN, Levin MJ, Johnson GR et al (2005) A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352:2271–2284. Scholar
  62. Ozaki T, Asano Y (2016) Development of varicella vaccine in Japan and future prospects. Vaccine 34:3427–3433. Scholar
  63. Ozaki T, Nagayoshi S, Morishima T et al (1978) Use of a live varicella vaccine for acute leukemic children shortly after exposure in a children’s ward. Biken J 21:69–72PubMedGoogle Scholar
  64. Pastuszak AL, Levy M, Schick B et al (1994) Outcome after maternal varicella infection in the first 20 weeks of pregnancy. N Engl J Med 330:901–905. Scholar
  65. Peters GA, Tyler SD, Carpenter JE et al (2012) The attenuated genotype of Varicella-Zoster Virus includes an ORF0 transitional stop codon mutation. J Virol 86:10695–10703. Scholar
  66. Qi Q, Cavanagh MM, Le Saux S et al (2016a) Diversification of the antigen-specific T cell receptor repertoire after varicella zoster vaccination. Sci Transl Med 8:332ra46. Scholar
  67. Qi Q, Cavanagh MM, Le Saux S et al (2016b) Defective T memory cell differentiation after Varicella Zoster vaccination in older individuals. PLoS Pathog 12:e1005892. Scholar
  68. Quinlivan ML, Gershon AA, Steinberg SP, Breuer J (2004) Rashes occurring after immunization with a mixture of viruses in the Oka vaccine are derived from single clones of virus. J Infect Dis 190:793–796. Scholar
  69. Sadaoka T, Depledge DP, Rajbhandari L et al (2016) In vitro system using human neurons demonstrates that varicella-zoster vaccine virus is impaired for reactivation, but not latency. Proc Natl Acad Sci U S A 113:E2403–E2412. Scholar
  70. Shapiro ED, Vazquez M, Esposito D et al (2011) Effectiveness of 2 doses of varicella vaccine in children. J Infect Dis 203:312–315. Scholar
  71. Takahashi M, Otsuka T, Okuno Y et al (1974) Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 2:1288–1290CrossRefPubMedGoogle Scholar
  72. Takayama N, Minamitani M, Takayama M (1997) High incidence of breakthrough varicella observed in healthy Japanese children immunized with live attenuated varicella vaccine (Oka strain). Acta Paediatr Jpn 39:663–668CrossRefPubMedGoogle Scholar
  73. Thiele S, Borschewski A, Küchler J et al (2011) Molecular analysis of varicella vaccines and varicella-zoster virus from vaccine-related skin lesions. Clin Vaccine Immunol 18:1058–1066. Scholar
  74. Vandepapelière P, Horsmans Y, Moris P et al (2008) Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 26:1375–1386. Scholar
  75. Victoria JG, Wang C, Jones MS et al (2010) Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J Virol 84:6033–6040. Scholar
  76. Weinmann S, Chun C, Schmid DS et al (2013) Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005–2009. J Infect Dis 208:1859–1868. Scholar
  77. WHO experts committee on biological standardization (1994) Requirements for varicella vaccine (live)Google Scholar
  78. Yoshikawa T, Ando Y, Nakagawa T, Gomi Y (2016) Safety profile of the varicella vaccine (Oka vaccine strain) based on reported cases from 2005 to 2015 in Japan. Vaccine 34:4943–4947. Scholar
  79. Zerboni L, Hinchliffe S, Sommer MH et al (2005a) Analysis of varicella zoster virus attenuation by evaluation of chimeric parent Oka/vaccine Oka recombinant viruses in skin xenografts in the SCIDhu mouse model. Virology 332:337–346. Scholar
  80. Zerboni L, Ku C-C, Jones CD et al (2005b) Varicella-zoster virus infection of human dorsal root ganglia in vivo. Proc Natl Acad Sci U S A 102:6490–6495. Scholar
  81. Zerboni L, Sobel RA, Lai M et al (2012) Apparent expression of varicella-zoster virus proteins in latency resulting from reactivity of murine and rabbit antibodies with human blood group a determinants in sensory neurons. J Virol 86:578–583. Scholar
  82. Zerboni L, Sen N, Oliver SL, Arvin AM (2014) Molecular mechanisms of varicella zoster virus pathogenesis. Nat Rev Microbiol 12:197–210. Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Division of Clinical Virology, Center for Infectious DiseasesKobe University Graduate School of MedicineKobeJapan

Personalised recommendations